Secondary hyperparathyroidism is a disorder of the parathyroid glands that causes an increase in the production of parathyroid hormone (PTH) to keep calcium levels in the blood at normal levels. The condition is caused by an underlying chronic renal disease in which the kidneys do not clear the phosphorus in the blood. Secondary Hyperparathyroidism is caused by an excess of phosphorus in the blood, which causes a drop in calcium levels. PTH levels are high in the early phases of secondary hyperparathyroidism, although calcium levels are low or normal. PTH overproduction causes cardiovascular issues, low blood count, improper fat and sugar metabolism, bone thinning, and calciphylaxis. Vitamin D deficiency, vitamin D-resistant rickets, high aberrant magnesium levels, starvation, and gastrointestinal malabsorption syndrome are some of the other reasons of secondary hyperparathyroidism.

One of the key causes for the expansion of the secondary hyperparathyroidism treatment Market is the rising frequency of chronic renal disease, which is a leading cause of secondary hyperparathyroidism. In addition, the market is expected to grow due to an increase in disease-related research and product approvals. In Europe, for example, Amgen's Parsabiv (etelcalcetide) was approved in 2016 for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis. Furthermore, the market is developing due to the increasing number of items in development. However, the severe side effects of secondary hyperparathyroidism medication, such as diarrhoea, vomiting, muscle spasms, and a reduction in serum calcium, could hurt the market. Furthermore, because of hypotension and impaired myocardial performance, a fall in serum calcium levels as a result of treatment increases the risk of heart failure.

Therapy type, distribution channel, and location can all be used to segment the secondary hyperparathyroidism treatment market. The market can be divided into surgical and drug class based on the type of therapy. Vitamin D and derivatives, calcimimetics, and phosphate binders are sub-categories of the drug class. Calcimimetics, a medication class with the potential to attach to parathyroid cell receptors and lower calcium levels in blood serum, are expected to experience significant increase. Furthermore, the increasing number of calcimimetics product approvals contributes to the segment's quick expansion. The market can be divided into hospital pharmacies and retail pharmacies based on the distribution route. During the forecast period, hospital pharmacies are expected to dominate the market.

North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa account for the majority of the secondary hyperparathyroidism treatment market. North America is expected to have a large proportion of the secondary hyperparathyroidism therapy market. This is due to a well-developed health-care infrastructure, increased public awareness, and favourable reimbursement conditions. Europe is expected to be the market's second-to-last area. However, due to the region's weak economic growth, market growth is expected to be hampered. During the projected period, the Asia Pacific market is expected to grow at a healthy rate.   

Amgen Inc., OPKO Health, Inc., AbbVie Inc., Shire Plc, F. Hoffmann-La Roche AG, Sanofi S.A., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc, KAI Pharmaceuticals, Leo Pharma A/S, and Deltanoid Pharmaceuticals are among the leading competitors in the secondary hyperparathyroidism treatment market.